66 filings
Page 3 of 4
8-K
tgqad rrd9lgw
5 Oct 21
CLN7 program currently in Phase 1 clinical proof-of-concept trial with preliminary data anticipated by year-end 2021
7:15am
8-K
vbdp 42jav4
16 Aug 21
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:16am
8-K
eo9kavb viteign3x
29 Jun 21
Regulation FD Disclosure
7:30am
8-K
ql90r3t62 7m1y7
28 Jun 21
Regulation FD Disclosure
7:33am
8-K
3nv hz7ndr76h
17 Jun 21
Submission of Matters to a Vote of Security Holders
5:12pm
8-K
2ddepxp b3pqi
11 May 21
Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
7:15am
8-K
ft4cds
14 Apr 21
Regulation FD Disclosure
4:20pm
8-K
2o2b6jqx
12 Apr 21
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy
7:15am
8-K
iob raxozt
9 Mar 21
Taysha to have an exclusive option on new payloads, constructs, and intellectual property arising from research conducted under the agreement
7:32am
8-K/A
grqtg715bc144qtec29f
5 Mar 21
Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update
4:30pm
8-K
dpellf5t y57qj
3 Mar 21
Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
7:15am
8-K
bnd4twc3l
12 Feb 21
Other Events
4:30pm
8-K
za7f3t1
1 Feb 21
Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook
7:15am
8-K
opj6p
19 Jan 21
Other Events
7:15am
8-K
4a18hmq
15 Jan 21
Entry into a Material Definitive Agreement
4:33pm
8-K
emopexxk
21 Dec 20
Other Events
7:15am
8-K
1j5p78 k3
17 Dec 20
Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility
4:16pm
8-K
yg9cszva
3 Dec 20
Other Events
7:15am
8-K
6zgkcrqkg4l
24 Nov 20
Taysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors
7:15am
8-K
qal6rjdwyp
12 Nov 20
Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update
4:25pm